SX
SXTPW
60 DEGREES PHARMACEUTICALS, INC.
$0.0380
0.00%
$102.9K
No data for this timeframe.
Vol
Market Cap$102.9K
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$30.00
Inst. Activity0 buys / 1 sells
SEC Reports1
Recent Activity
May 19, 2026
SEC
Eric Francois filed a Form 3 initial statement of beneficial ownership reporting zero securities owned in 60 Degrees Pha
3 — Impact 3/10
Inst.
UBS Group AG — TRIM
814 shares ($30.00)
Inst.
UBS Group AG — DOUBLED
506 shares ($15.00)
May 26, 2026
fda
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
60 Degrees Pharma enrolls first 2026 babesiosis trial patient ahead of schedule, supporting possible
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $30.00 | TRIM |
1 institutional holders with $30.00 total value (814 shares) as of 2025-Q3. Top holders: UBS. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 814 | $30.00 | 100.0% | TRIM -45.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | TRIM | 1,501 | 814 | -45.8% | $30.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 80 | 506 | +532.5% | $15.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 3.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -39.9% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -49.9% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -10.5% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 77.8% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 26, 2026
fda
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
60 Degrees Pharma enrolls first 2026 babesiosis trial patient ahead of schedule, supporting possible early interim analysis.
May 15, 2026
earnings
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
Apr 15, 2026
other
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
ARAKODA® now available via Runway Health, enabling U.S. travelers to access once-weekly malaria prevention through a convenient telehealth platform.
Mar 31, 2026
earnings
60 Degrees Pharmaceuticals Announces 2025 Annual Results
60 Degrees Pharma (Nasdaq: SXTP) FY25 revenue +65% to $1.0M; improved net loss; continued clinical, commercial, and partnership momentum.
Mar 18, 2026
regulatory
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strateg
Mar 11, 2026
other
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
All three patients in 60 Degrees Pharma’s expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline r